Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Specific T Cell Responses against Minor Histocompatibility Antigens Cannot Generally Be Explained by Absence of Their Allelic Counterparts on the Cell Surface.

Bijen HM, Hassan C, Kester MGD, Janssen GMC, Hombrink P, de Ru AH, Drijfhout JW, Meiring HD, de Jong AP, Falkenburg JHF, Jimenez CR, Heemskerk MHM, van Veelen PA.

Proteomics. 2018 Jun;18(12):e1700250. doi: 10.1002/pmic.201700250. Epub 2018 Feb 23.

PMID:
29251415
2.

A Specialist Macaque MHC Class I Molecule with HLA-B*27-like Peptide-Binding Characteristics.

de Groot NG, Heijmans CMC, de Ru AH, Janssen GMC, Drijfhout JW, Otting N, Vangenot C, Doxiadis GGM, Koning F, van Veelen PA, Bontrop RE.

J Immunol. 2017 Nov 15;199(10):3679-3690. doi: 10.4049/jimmunol.1700502. Epub 2017 Oct 11.

PMID:
29021373
3.

Breach of autoreactive B cell tolerance by post-translationally modified proteins.

Dekkers JS, Verheul MK, Stoop JN, Liu B, Ioan-Facsinay A, van Veelen PA, de Ru AH, Janssen GMC, Hegen M, Rapecki S, Huizinga TWJ, Trouw LA, Toes REM.

Ann Rheum Dis. 2017 Aug;76(8):1449-1457. doi: 10.1136/annrheumdis-2016-210772. Epub 2017 Apr 25.

PMID:
28442530
4.

TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.

Jahn L, Hombrink P, Hagedoorn RS, Kester MG, van der Steen DM, Rodriguez T, Pentcheva-Hoang T, de Ru AH, Schoonakker MP, Meeuwsen MH, Griffioen M, van Veelen PA, Falkenburg JH, Heemskerk MH.

Blood. 2017 Mar 9;129(10):1284-1295. doi: 10.1182/blood-2016-09-737536. Epub 2017 Jan 4.

5.

CD4 T-cell cytokines synergize to induce proliferation of malignant and nonmalignant innate intraepithelial lymphocytes.

Kooy-Winkelaar YM, Bouwer D, Janssen GM, Thompson A, Brugman MH, Schmitz F, de Ru AH, van Gils T, Bouma G, van Rood JJ, van Veelen PA, Mearin ML, Mulder CJ, Koning F, van Bergen J.

Proc Natl Acad Sci U S A. 2017 Feb 7;114(6):E980-E989. doi: 10.1073/pnas.1620036114. Epub 2017 Jan 3.

6.

Parallel reaction monitoring of clinical Mycobacterium tuberculosis lineages reveals pre-existent markers of rifampicin tolerance in the emerging Beijing lineage.

de Keijzer J, Mulder A, de Ru AH, van Soolingen D, van Veelen PA.

J Proteomics. 2017 Jan 6;150:9-17. doi: 10.1016/j.jprot.2016.08.022. Epub 2016 Aug 26.

PMID:
27576137
7.

Multimodal Mass Spectrometry Imaging of N-Glycans and Proteins from the Same Tissue Section.

Heijs B, Holst S, Briaire-de Bruijn IH, van Pelt GW, de Ru AH, van Veelen PA, Drake RR, Mehta AS, Mesker WE, Tollenaar RA, Bovée JV, Wuhrer M, McDonnell LA.

Anal Chem. 2016 Aug 2;88(15):7745-53. doi: 10.1021/acs.analchem.6b01739. Epub 2016 Jul 14.

PMID:
27373711
8.

Thioridazine Alters the Cell-Envelope Permeability of Mycobacterium tuberculosis.

de Keijzer J, Mulder A, de Haas PE, de Ru AH, Heerkens EM, Amaral L, van Soolingen D, van Veelen PA.

J Proteome Res. 2016 Jun 3;15(6):1776-86. doi: 10.1021/acs.jproteome.5b01037. Epub 2016 May 9.

PMID:
27068340
9.

Dendritic Cells Guide Islet Autoimmunity through a Restricted and Uniquely Processed Peptidome Presented by High-Risk HLA-DR.

van Lummel M, van Veelen PA, de Ru AH, Janssen GM, Pool J, Laban S, Joosten AM, Nikolic T, Drijfhout JW, Mearin ML, Aanstoot HJ, Peakman M, Roep BO.

J Immunol. 2016 Apr 15;196(8):3253-63. doi: 10.4049/jimmunol.1501282. Epub 2016 Mar 4.

10.

Mechanisms of Phenotypic Rifampicin Tolerance in Mycobacterium tuberculosis Beijing Genotype Strain B0/W148 Revealed by Proteomics.

de Keijzer J, Mulder A, de Beer J, de Ru AH, van Veelen PA, van Soolingen D.

J Proteome Res. 2016 Apr 1;15(4):1194-204. doi: 10.1021/acs.jproteome.5b01073. Epub 2016 Mar 24.

PMID:
26930559
11.

Human islets and dendritic cells generate post-translationally modified islet autoantigens.

McLaughlin RJ, de Haan A, Zaldumbide A, de Koning EJ, de Ru AH, van Veelen PA, van Lummel M, Roep BO.

Clin Exp Immunol. 2016 Aug;185(2):133-40. doi: 10.1111/cei.12775. Epub 2016 May 17.

12.

Discovery of a Selective Islet Peptidome Presented by the Highest-Risk HLA-DQ8trans Molecule.

van Lummel M, van Veelen PA, de Ru AH, Pool J, Nikolic T, Laban S, Joosten A, Drijfhout JW, Gómez-Touriño I, Arif S, Aanstoot HJ, Peakman M, Roep BO.

Diabetes. 2016 Mar;65(3):732-41. doi: 10.2337/db15-1031. Epub 2015 Dec 30.

13.

Proteasomal Degradation of Proinsulin Requires Derlin-2, HRD1 and p97.

Hoelen H, Zaldumbide A, van Leeuwen WF, Torfs EC, Engelse MA, Hassan C, Lebbink RJ, de Koning EJ, Resssing ME, de Ru AH, van Veelen PA, Hoeben RC, Roep BO, Wiertz EJ.

PLoS One. 2015 Jun 24;10(6):e0128206. doi: 10.1371/journal.pone.0128206. eCollection 2015.

14.

ICL-induced miR139-3p and miR199a-3p have opposite roles in hematopoietic cell expansion and leukemic transformation.

Alemdehy MF, Haanstra JR, de Looper HW, van Strien PM, Verhagen-Oldenampsen J, Caljouw Y, Sanders MA, Hoogenboezem R, de Ru AH, Janssen GM, Smetsers SE, Bierings MB, van Veelen PA, von Lindern M, Touw IP, Erkeland SJ.

Blood. 2015 Jun 18;125(25):3937-48. doi: 10.1182/blood-2014-11-612507. Epub 2015 Mar 16.

15.

Temporal SILAC-based quantitative proteomics identifies host factors involved in chikungunya virus replication.

Treffers EE, Tas A, Scholte FE, Van MN, Heemskerk MT, de Ru AH, Snijder EJ, van Hemert MJ, van Veelen PA.

Proteomics. 2015 Jul;15(13):2267-80. doi: 10.1002/pmic.201400581. Epub 2015 Apr 22.

PMID:
25764339
16.

Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte-Derived HLA-Ligandome Using a Reverse Immunology Approach.

Hombrink P, Hassan C, Kester MG, Jahn L, Pont MJ, de Ru AH, van Bergen CA, Griffioen M, Falkenburg JH, van Veelen PA, Heemskerk MH.

Clin Cancer Res. 2015 May 1;21(9):2177-86. doi: 10.1158/1078-0432.CCR-14-2188. Epub 2015 Jan 14.

17.

Comprehensive analysis of the mouse brain proteome sampled in mass spectrometry imaging.

Heijs B, Carreira RJ, Tolner EA, de Ru AH, van den Maagdenberg AM, van Veelen PA, McDonnell LA.

Anal Chem. 2015 Feb 3;87(3):1867-75. doi: 10.1021/ac503952q. Epub 2015 Jan 13.

PMID:
25535922
18.

Naturally processed non-canonical HLA-A*02:01 presented peptides.

Hassan C, Chabrol E, Jahn L, Kester MG, de Ru AH, Drijfhout JW, Rossjohn J, Falkenburg JH, Heemskerk MH, Gras S, van Veelen PA.

J Biol Chem. 2015 Jan 30;290(5):2593-603. doi: 10.1074/jbc.M114.607028. Epub 2014 Dec 12.

19.

Accurate quantitation of MHC-bound peptides by application of isotopically labeled peptide MHC complexes.

Hassan C, Kester MG, Oudgenoeg G, de Ru AH, Janssen GM, Drijfhout JW, Spaapen RM, Jiménez CR, Heemskerk MH, Falkenburg JH, van Veelen PA.

J Proteomics. 2014 Sep 23;109:240-4. doi: 10.1016/j.jprot.2014.07.009. Epub 2014 Jul 19.

PMID:
25050860
20.

Disclosure of selective advantages in the "modern" sublineage of the Mycobacterium tuberculosis Beijing genotype family by quantitative proteomics.

de Keijzer J, de Haas PE, de Ru AH, van Veelen PA, van Soolingen D.

Mol Cell Proteomics. 2014 Oct;13(10):2632-45. doi: 10.1074/mcp.M114.038380. Epub 2014 Jul 14.

21.

Unique peptide-binding motif for Mamu-B*037:01: an MHC class I allele common to Indian and Chinese rhesus macaques.

de Groot NG, Heijmans CM, de Ru AH, Hassan C, Otting N, Doxiadis GG, Koning F, van Veelen PA, Bontrop RE.

Immunogenetics. 2013 Dec;65(12):897-900. doi: 10.1007/s00251-013-0734-5. Epub 2013 Sep 17.

PMID:
24042460
22.

The human leukocyte antigen-presented ligandome of B lymphocytes.

Hassan C, Kester MG, de Ru AH, Hombrink P, Drijfhout JW, Nijveen H, Leunissen JA, Heemskerk MH, Falkenburg JH, van Veelen PA.

Mol Cell Proteomics. 2013 Jul;12(7):1829-43. doi: 10.1074/mcp.M112.024810. Epub 2013 Mar 12.

23.

Discovery of T cell epitopes implementing HLA-peptidomics into a reverse immunology approach.

Hombrink P, Hassan C, Kester MG, de Ru AH, van Bergen CA, Nijveen H, Drijfhout JW, Falkenburg JH, Heemskerk MH, van Veelen PA.

J Immunol. 2013 Apr 15;190(8):3869-77. doi: 10.4049/jimmunol.1202351. Epub 2013 Mar 8.

24.

Efficient -2 frameshifting by mammalian ribosomes to synthesize an additional arterivirus protein.

Fang Y, Treffers EE, Li Y, Tas A, Sun Z, van der Meer Y, de Ru AH, van Veelen PA, Atkins JF, Snijder EJ, Firth AE.

Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):E2920-8. doi: 10.1073/pnas.1211145109. Epub 2012 Oct 4.

25.

Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2.

Lampen MH, Hassan C, Sluijter M, Geluk A, Dijkman K, Tjon JM, de Ru AH, van der Burg SH, van Veelen PA, van Hall T.

Mol Immunol. 2013 Jan;53(1-2):126-31. doi: 10.1016/j.molimm.2012.07.009. Epub 2012 Aug 13.

PMID:
22898188
26.

Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells.

van Luijn MM, van de Loosdrecht AA, Lampen MH, van Veelen PA, Zevenbergen A, Kester MG, de Ru AH, Ossenkoppele GJ, van Hall T, van Ham SM.

PLoS One. 2012;7(4):e34649. doi: 10.1371/journal.pone.0034649. Epub 2012 Apr 26.

27.

Efficiency and mechanism of antigen-specific CD8+ T-cell activation using synthetic long peptides.

Zandvliet ML, Kester MG, van Liempt E, de Ru AH, van Veelen PA, Griffioen M, Guchelaar HJ, Falkenburg JH, Meij P.

J Immunother. 2012 Feb-Mar;35(2):142-53. doi: 10.1097/CJI.0b013e318243f1ed.

PMID:
22306902
28.

Allo-HLA-reactive T cells inducing graft-versus-host disease are single peptide specific.

Amir AL, van der Steen DM, Hagedoorn RS, Kester MG, van Bergen CA, Drijfhout JW, de Ru AH, Falkenburg JH, van Veelen PA, Heemskerk MH.

Blood. 2011 Dec 22;118(26):6733-42. doi: 10.1182/blood-2011-05-354787. Epub 2011 Oct 4.

29.

PRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer.

Amir AL, van der Steen DM, van Loenen MM, Hagedoorn RS, de Boer R, Kester MD, de Ru AH, Lugthart GJ, van Kooten C, Hiemstra PS, Jedema I, Griffioen M, van Veelen PA, Falkenburg JH, Heemskerk MH.

Clin Cancer Res. 2011 Sep 1;17(17):5615-25. doi: 10.1158/1078-0432.CCR-11-1066. Epub 2011 Jul 19.

30.

MiR-17/20/93/106 promote hematopoietic cell expansion by targeting sequestosome 1-regulated pathways in mice.

Meenhuis A, van Veelen PA, de Looper H, van Boxtel N, van den Berge IJ, Sun SM, Taskesen E, Stern P, de Ru AH, van Adrichem AJ, Demmers J, Jongen-Lavrencic M, Löwenberg B, Touw IP, Sharp PA, Erkeland SJ.

Blood. 2011 Jul 28;118(4):916-25. doi: 10.1182/blood-2011-02-336487. Epub 2011 May 31.

31.

HSPVdb--the Human Short Peptide Variation Database for improved mass spectrometry-based detection of polymorphic HLA-ligands.

Nijveen H, Kester MG, Hassan C, Viars A, de Ru AH, de Jager M, Falkenburg JH, Leunissen JA, van Veelen PA.

Immunogenetics. 2011 Mar;63(3):143-53. doi: 10.1007/s00251-010-0497-1. Epub 2010 Dec 2.

32.

AIDS-protective HLA-B*27/B*57 and chimpanzee MHC class I molecules target analogous conserved areas of HIV-1/SIVcpz.

de Groot NG, Heijmans CM, Zoet YM, de Ru AH, Verreck FA, van Veelen PA, Drijfhout JW, Doxiadis GG, Remarque EJ, Doxiadis II, van Rood JJ, Koning F, Bontrop RE.

Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15175-80. doi: 10.1073/pnas.1009136107. Epub 2010 Aug 9.

33.

Dominance of an alternative CLIP sequence in the celiac disease associated HLA-DQ2 molecule.

Wiesner M, Stepniak D, de Ru AH, Moustakis AK, Drijfhout JW, Papadopoulos GK, van Veelen PA, Koning F.

Immunogenetics. 2008 Sep;60(9):551-5. doi: 10.1007/s00251-008-0310-6. Epub 2008 Jun 27.

34.

Large-scale characterization of natural ligands explains the unique gluten-binding properties of HLA-DQ2.

Stepniak D, Wiesner M, de Ru AH, Moustakas AK, Drijfhout JW, Papadopoulos GK, van Veelen PA, Koning F.

J Immunol. 2008 Mar 1;180(5):3268-78.

35.

Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene.

van Bergen CA, Kester MG, Jedema I, Heemskerk MH, van Luxemburg-Heijs SA, Kloosterboer FM, Marijt WA, de Ru AH, Schaafsma MR, Willemze R, van Veelen PA, Falkenburg JH.

Blood. 2007 May 1;109(9):4089-96. Epub 2007 Jan 18.

36.

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.

Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, Griekspoor A, Mesman E, Verreck FA, Spits H, Schlom J, van Veelen P, Neefjes JJ.

J Exp Med. 2006 May 15;203(5):1259-71. Epub 2006 Apr 24.

37.

Proteosomal degradation of BCR/ABL protein can generate an HLA-A*0301-restricted peptide, but high-avidity T cells recognizing this leukemia-specific antigen were not demonstrated.

Posthuma EF, van Bergen CA, Kester MG, de Paus RA, van Veelen PA, de Ru AH, Drijfhout JW, Lurvink EG, Willemze R, Falkenburg JH.

Haematologica. 2004 Sep;89(9):1062-71.

38.

Morphological changes during dendritic cell maturation correlate with cofilin activation and translocation to the cell membrane.

Verdijk P, van Veelen PA, de Ru AH, Hensbergen PJ, Mizuno K, Koerten HK, Koning F, Tensen CP, Mommaas AM.

Eur J Immunol. 2004 Jan;34(1):156-64.

39.

A structural model of pestivirus E(rns) based on disulfide bond connectivity and homology modeling reveals an extremely rare vicinal disulfide.

Langedijk JP, van Veelen PA, Schaaper WM, de Ru AH, Meloen RH, Hulst MM.

J Virol. 2002 Oct;76(20):10383-92.

Supplemental Content

Loading ...
Support Center